Wright Medical Group NV (NASDAQ:WMGI) SVP Andrew C. Morton sold 2,173 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $32.50, for a total transaction of $70,622.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Wright Medical Group stock traded down $0.66 during trading on Friday, reaching $31.83. The company had a trading volume of 1,497,271 shares, compared to its average volume of 1,208,807. The firm has a market cap of $4.10 billion, a PE ratio of 812.25, a price-to-earnings-growth ratio of 10.16 and a beta of 0.97. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.70 and a current ratio of 0.91. Wright Medical Group NV has a fifty-two week low of $22.55 and a fifty-two week high of $32.86.
Wright Medical Group (NASDAQ:WMGI) last issued its earnings results on Tuesday, May 7th. The medical device company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. The business had revenue of $230.13 million for the quarter, compared to analyst estimates of $226.10 million. Wright Medical Group had a negative net margin of 20.81% and a positive return on equity of 0.84%. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.01) EPS. On average, equities analysts predict that Wright Medical Group NV will post 0.21 earnings per share for the current year.
A number of brokerages have commented on WMGI. BidaskClub upgraded shares of Wright Medical Group from a “hold” rating to a “buy” rating in a report on Tuesday. Oppenheimer set a $34.00 price objective on shares of Wright Medical Group and gave the stock a “hold” rating in a report on Wednesday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Wright Medical Group in a report on Wednesday, April 10th. BMO Capital Markets boosted their price objective on shares of Wright Medical Group from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Wright Medical Group in a report on Monday, March 11th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $34.92.
Wright Medical Group Company Profile
Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth.
See Also: Discount Rate
Receive News & Ratings for Wright Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wright Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.